The family of coronaviruses (CoVs) uses the autophagy machinery of host cells to promote their growth and replication; thus, this process stands out as a potential target to combat COVID-19. Considering the different roles of autophagy during viral infection, including SARS-CoV-2 infection, in this review, we discuss several clinically used drugs that have effects at different stages of autophagy. Among them, we mention (1) lysosomotropic agents, which can prevent CoVs infection by alkalinizing the acid pH in the endolysosomal system, such as chloroquine and hydroxychloroquine, azithromycin, artemisinins, two-pore channel modulators and imatinib; (2) protease inhibitors that can inhibit the proteolytic cleavage of the spike CoVs protein, which is necessary for viral entry into host cells, such as camostat mesylate, lopinavir, umifenovir and teicoplanin and (3) modulators of PI3K/AKT/mTOR signaling pathways, such as rapamycin, heparin, glucocorticoids, angiotensin-converting enzyme inhibitors (IECAs) and cannabidiol. Thus, this review aims to highlight and discuss autophagy-related drugs for COVID-19, from in vitro to in vivo studies. We identified specific compounds that may modulate autophagy and exhibit antiviral properties. We hope that research initiatives and efforts will identify novel or “off-label” drugs that can be used to effectively treat patients infected with SARS-CoV-2, reducing the risk of mortality.

Pharmacological modulators of autophagy as a potential strategy for the treatment of covid-19 / Pereira, G. J. D. S.; Leao, A. H. F. F.; Erustes, A. G.; Morais, I. B. M.; Vrechi, T. A. M.; Zamarioli, L. S.; Pereira, C. A. S.; Marchioro, L. O.; Sperandio, L. P.; Lins, I. V. F.; Piacentini, M.; Fimia, G. M.; Reckziegel, P.; Smaili, S. S.; Bincoletto, C.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 22:8(2021). [10.3390/ijms22084067]

Pharmacological modulators of autophagy as a potential strategy for the treatment of covid-19

Fimia G. M.;
2021

Abstract

The family of coronaviruses (CoVs) uses the autophagy machinery of host cells to promote their growth and replication; thus, this process stands out as a potential target to combat COVID-19. Considering the different roles of autophagy during viral infection, including SARS-CoV-2 infection, in this review, we discuss several clinically used drugs that have effects at different stages of autophagy. Among them, we mention (1) lysosomotropic agents, which can prevent CoVs infection by alkalinizing the acid pH in the endolysosomal system, such as chloroquine and hydroxychloroquine, azithromycin, artemisinins, two-pore channel modulators and imatinib; (2) protease inhibitors that can inhibit the proteolytic cleavage of the spike CoVs protein, which is necessary for viral entry into host cells, such as camostat mesylate, lopinavir, umifenovir and teicoplanin and (3) modulators of PI3K/AKT/mTOR signaling pathways, such as rapamycin, heparin, glucocorticoids, angiotensin-converting enzyme inhibitors (IECAs) and cannabidiol. Thus, this review aims to highlight and discuss autophagy-related drugs for COVID-19, from in vitro to in vivo studies. We identified specific compounds that may modulate autophagy and exhibit antiviral properties. We hope that research initiatives and efforts will identify novel or “off-label” drugs that can be used to effectively treat patients infected with SARS-CoV-2, reducing the risk of mortality.
2021
autophagy; COVID-19; pharmacology
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Pharmacological modulators of autophagy as a potential strategy for the treatment of covid-19 / Pereira, G. J. D. S.; Leao, A. H. F. F.; Erustes, A. G.; Morais, I. B. M.; Vrechi, T. A. M.; Zamarioli, L. S.; Pereira, C. A. S.; Marchioro, L. O.; Sperandio, L. P.; Lins, I. V. F.; Piacentini, M.; Fimia, G. M.; Reckziegel, P.; Smaili, S. S.; Bincoletto, C.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 22:8(2021). [10.3390/ijms22084067]
File allegati a questo prodotto
File Dimensione Formato  
daSilvaPereira_Pharmacological-modulators_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 5.96 MB
Formato Adobe PDF
5.96 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1572503
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact